Fertility is a complex combination of various elements; however, age is perhaps the most significant factor. Women - and to a slightly lesser degree, men - experience their reproductive well-being and the probability of conception change as they age.

It would be reassuring for individuals who plan to start or are starting families later in life if they knew more about these effects and how age affects fertility and in vitro fertilization (IVF) success rates.

The Effect of Age on Female Fertility

Female fertility takes a dive in the late 20s and early 30s, and then it dramatically drops after the age of 35. The reason for this decline in female fertility is largely attributed to the reduced amount and quality of eggs. Women are born with only an approximate number of eggs in their lifetime, which continues to decrease with age. In fact, at age 40, there is very little chance of becoming pregnant without advanced reproductive technology, and the risk of eggs having significant chromosomal abnormalities in the egg increases dramatically, hence increased miscarriage and birth defects.

It's not just the female side that declines with age; male fertility declines as well. Although the decline is probably less dramatic, the quality of sperm decreases, mainly in the areas of motility and morphology, which adversely affects male fertility as well, unfortunately.

IVF and Age

IVF has emerged as a potent of choice for couples that have been facing fertility issues most especially those related to age. Age, however, still a decisive success factor in IVF treatment. According to different studies, it has been indicated that the great success rate achieved from IVF is when the females are below 35 years with the overall live birth rate per cycle close to 40-50%. The percentage rate stands at around 40-50% for women aged 32-34, followed by about 30-40% for women aged 35-37, and approximately 20-30% for women aged 38-40. Success rates hit a mere 5-10% per cycle for women older than 40. Such is why age becomes a critical issue for those attempting ART.

Why Are Success Rates Dropping?

The reduced success rate of IVF with increasing age has been mostly attributed to the conditions such as egg quality, hormonal imbalances, and a higher risk of existing medical conditions. With time, the risk of having medical conditions such as endometriosis or uterine fibroids to make the pregnancy complicated also increases. Older eggs are also more likely to have chromosomal defects, which may lead to failures at the implantation or miscarriages.

In men, though the quality of sperms is affected by the age, the decline is not that steep as it is in the case of women. The opposite, however has proved true with advanced paternal age also leading to several risks such as genetic mutations and various developmental disorders in their offspring.

Overcoming Age-Related Fertility Issues

For those who would wish to avoid age-related fertility issues, it's not too early to take some proactive measures. Early consultation with a fertility specialist can help in assessing one's individual circumstances and then take expert advice on the best course of action. Then, there is egg freezing that helps women preserve their eggs at a relatively younger age for potential use or the use of donor eggs that can greatly increase chances for older women.

Lifestyle choices contribute significantly to fertility. Proper weight maintenance, nonsmoking, no dependence on heavy alcohol intake, and less stress are some of the indicators of maintaining a healthy reproductive system that can enhance the chances and possibility of successful IVF treatments.

Rare diseases may be individually uncommon, but together they represent a large and persistent care gap. More than 300 million people globally live with a rare condition, and when families and caregivers are counted, the impact touches over one billion lives. The economic burden is estimated to exceed $7 trillion each year.

In India, the challenge is compounded by geography, uneven specialist availability and the lifelong nature of many rare conditions. The question is no longer whether the system recognises the need, but whether it can deliver continuous care at scale.

Why Patients Still Struggle To Reach Care

For most rare disease patients, the hardest part is not always the science but the pathway to care. Diagnosis is often delayed, sometimes by years. Patients move between providers carrying incomplete records. Specialist centres are concentrated in a few large cities, forcing families to travel repeatedly for consultations that may last only minutes. This is both financially draining and clinically inefficient.

Telemedicine is beginning to ease some of this pressure. Virtual consultations allow specialists to extend their reach beyond metropolitan clusters. For families in tier two and tier three locations, this can mean earlier clinical input and fewer avoidable journeys.

Remote monitoring tools are also shifting care from episodic hospital visits to continuous oversight, which is particularly valuable for conditions that require close tracking over time.

Why Data Matters More Than Ever

If access is the visible challenge, data fragmentation is the structural one. Rare disease information remains scattered across hospitals, laboratories and individual case files. This weak visibility affects everything from prevalence estimates to therapy development. Policymakers struggle to size the problem accurately. Clinicians miss longitudinal patterns. Industry investment becomes harder to justify.

Digital health systems can address this by creating longitudinal patient records that follow individuals across providers. Even relatively modest steps such as strengthening diagnostic reporting or building disease registries can significantly improve coordination. For rare diseases, where patient numbers are small and widely dispersed, structured data is not a luxury. It is the backbone of effective care.

India’s Digital Opportunity

India has begun building the rails needed for this transition. The Ayushman Bharat Digital Mission is creating a national health data architecture anchored in unique health IDs and interoperable records. If applied rigorously to rare diseases, this infrastructure can support lifelong patient tracking, improve referral accuracy and give policymakers clearer visibility into disease burden.

Interoperability will determine how far this effort goes. The growing adoption of FHIR standards and API led systems is slowly allowing previously disconnected hospital platforms to exchange clinical information. For rare disease patients, whose care often spans multiple providers and years of follow up, this continuity is not technical detail. It is essential to safe treatment.

AI Moves From Promise To Practice

Artificial intelligence is also starting to show practical value. Globally, AI based clinical decision support tools are being used to flag potential rare disease cases hidden within routine health records. This matters because many rare conditions present with non specific symptoms and are frequently missed in early stages.

Collaborations between technology firms and pharmaceutical companies are demonstrating how electronic health record analysis, suspect patient lists and longitudinal data can help clinicians triage cases earlier for confirmatory testing. As these tools mature and integrate into routine workflows, they could significantly shorten the diagnostic odyssey that rare disease families currently endure.

Engaging Patients Beyond The Clinic

At the patient level, the shift is becoming more practical and visible. Tools that let people log symptoms, get medication reminders and share updates in real time are helping them stay more consistent with treatment, while giving clinicians better insight between visits. For lifelong conditions, this kind of day to day support brings care into the flow of everyday life, where most disease management actually happens.

Federated data models add an important layer of trust. By enabling analysis across multiple small patient populations without moving sensitive personal data, they address both privacy concerns and the sample size limitations that have historically slowed rare disease research.

From Pilots to Systems

Progress is visible across both public and private sectors. Regulated digital health platforms are already supporting rare disease programmes in several countries. Industry collaborations are using AI to detect conditions that often go undiagnosed for years. Public genomic databases are generating new diagnoses by enabling experts to build on shared evidence.

India’s immediate task is to move beyond isolated pilots. Telemedicine networks must be tied to referral protocols and reimbursement pathways. Digital registries must be built with strong governance and patient trust. AI tools need to be embedded into everyday clinical workflows rather than remaining demonstration projects.

Why Investment Makes Fiscal Sense

Poorly managed rare diseases create avoidable hospitalisations, lost productivity and long term care costs. Evidence increasingly shows that targeted investments in data systems, screening and coordinated care can reduce downstream expenditure. For low- and middle-income countries working within tight health budgets, these are not marginal gains.

India already has many of the building blocks needed to improve rare disease care, from expanding digital health infrastructure to growing AI capabilities and increasing policy focus. The real test now is disciplined execution.

Telemedicine networks must deepen their reach, patient registries need to become reliable and usable, data must move securely across systems, and clinicians should have decision support tools that fit into everyday practice. Taken together, these steps can meaningfully narrow today’s access gaps.

Digital health will not make rare diseases any less complex. But if implemented thoughtfully, it can reduce distance, shorten delays and bring much needed continuity to care journeys that are currently fragmented. For families managing lifelong conditions, that would be a tangible and much overdue shift.

In India, it is not uncommon for families to travel across cities, sometimes across states, seeking answers for symptoms that simply don’t make sense. A child who is not meeting developmental milestones. A young adult with unexplained muscle weakness. Recurrent hospital visits with no clear diagnosis.

For many, this long and frustrating search for clarity is what medicine calls the diagnostic odyssey.

Rare diseases are individually uncommon, but collectively they affect millions of people worldwide. Rare diseases affect an estimated 263–446 million people worldwide, spanning every geography, healthcare system, and socioeconomic context. India alone is estimated to have 70 million people living with rare diseases.

Importantly, although 70%–80% of rare diseases are genetic in origin, routine medical practices often consider genetic testing only after years of inconclusive evaluations.

In India, this challenge is amplified by several factors, including limited awareness of rare conditions, uneven access to specialized testing across regions, and a tendency to treat symptoms individually rather than look for a unifying cause.

A child may see a neurologist for seizures, a gastroenterologist for feeding issues, and a developmental pediatrician for delays, without anyone connecting the dots.

Studies have shown that patients and their families frequently wait years before receiving a confirmed diagnosis. Globally, rare disease diagnosis can take anywhere between 5–30 years.

In a country like India, where healthcare expenses are often paid out-of-pocket, this prolonged uncertainty can be devastating. Beyond cost, there is the psychological toll; parents wondering if they missed something and adult patients often questioning whether their symptoms are “all in their head”. During this period, families undergo repeated tests, face conflicting opinions, and bear significant emotional and financial strains.

Research shows that families experience profound emotional burden during the diagnostic odyssey, including stress, anxiety, and feelings of isolation.

Why Do These Conditions Stay Undetected For Years?

In many cases, the explanation is written into a person’s DNA. Genetic disorders rarely announce themselves clearly; instead, they often mimic common illnesses. Fatigue may look like anemia, developmental delay may resemble a learning difficulty, and repeated infections might be treated as isolated events rather than part of a larger pattern. Because the symptoms overlap with more familiar conditions, doctors naturally begin by treating what appears most likely.

Most healthcare systems also follow a step-by-step diagnostic approach; rule out the common causes first, then move to less common ones if symptoms persist. While this method works well for typical illnesses, it can significantly delay answers for rare genetic conditions. Without looking directly at the genetic blueprint, the underlying cause may remain hidden, even as the visible symptoms are managed one at a time.

Today, advances in genomic technologies such as whole-exome sequencing (WES) and whole-genome sequencing (WGS) allow us to examine thousands of genes simultaneously. Rather than guessing which gene might be responsible, we can comprehensively analyze a patient’s DNA to search for answers.

Evidence increasingly supports the use of genomic sequencing earlier in the diagnosis and care of rare diseases. Similarly, studies highlight how genomic testing not only provides diagnoses but also directly influences treatment decisions and long-term care planning.

In the Indian context, integrating genetic testing earlier could transform care. Instead of years of fragmented consultations, patients could receive a precise diagnosis sooner. This clarity can:

• Prevent unnecessary or repeated investigations
• Guide appropriate treatment strategies
• Inform family members about potential risks
• Enable informed decisions about future pregnancies
• Equally important, it replaces uncertainty with understanding.

Encouragingly, awareness around rare diseases is growing in India, and conversations around early genomic testing are becoming more mainstream. As technology becomes more affordable and accessible, we have an opportunity to fundamentally change the patient journey.

No family should spend years searching for answers when science has the tools to help. By embracing genomic medicine earlier in the diagnostic pathway, we can shorten the odyssey, reduce suffering, and empower families with clarity.

Because when symptoms don’t add up, sometimes the answer lies written in our genes.

Former US president Bill Clinton’s recent public appearance has sparked inquires of Parkinson’s disease in the media. The video was made public by the GOP-led House Oversight Committee, and it showed Clinton alongside his legal team giving his testimony concerning his past associations with the late convicted sex offender Jeffery Epstein.

Social media users quickly pointed out that during the video, the former president’s hand visibly trembled as he raised his glass of water. Hand tremors are often associated with cognitive decline, as it is known as an early sign of Parkinson’s.

The footage, captured at his home in Chappaqua, New York, showed a specific moment where Clinton’s hands shook as Representative Nancy Mace questioned him.

Are Hand Tremors A Sign Of Parkinson’s?

According to Parkinson’s Foundation, for many, a tremor (shaking) is the first sign of Parkinson’s. The most common type is a "resting tremor." This means your hand or leg might shake while you are sitting still or walking, but the shaking usually stops or gets better when you actually use that body part like reaching out to grab a glass of water.

Most people with Parkinson’s (70% to 90%) will have a tremor at some point. Interestingly, patients who have a resting tremor often see their symptoms progress more slowly than those who don't.

Could Hand Tremors Indicate Other Issues?

WashU Medicine explains that essential tremor is the most common reason for shaky hands, but it’s different from Parkinson’s. With essential tremors, your hands shake while you are using them, like holding a deck of cards. Parkinson’s usually causes shaking only when hands are resting. So what are some factors that can cause hand tremors?

Lifestyle and Stress

Almost everyone has a tiny, invisible tremor. However, things like high stress, being very tired, or feeling angry can make that shake visible. Drinking too much caffeine or smoking cigarettes can also cause your hands to tremble temporarily until the stimulants leave.

Age

While anyone can develop a tremor, it is most common in people over age 65. This type of shaking is usually "benign," meaning it isn't dangerous. It mostly affects the hands, head, or voice, and rarely spreads to the legs or feet.

Medication Side Effects and Withdrawal

Sometimes, the medicine you take for other things is the culprit. Drugs for asthma, seizures, or depression can cause shakiness. Shaking can also happen if you are going through alcohol withdrawal or using tobacco, as these substances directly affect your nervous system.

Potential Underlying Health Conditions

Hand tremors can sometimes be a "warning light" for other health issues. Problems like an overactive thyroid, or rare conditions where copper builds up in the body, can cause shaking. A doctor can run simple tests to see if these are the cause.

Clinton’s History with "Aging Tremors"

While the footage may appear concerning to new viewers, these tremors are a documented part of Clinton's health history. As far back as 2013, the 42nd President addressed similar concerns, clarifying that he had undergone medical testing to rule out Parkinson’s.

At the time, Clinton explained that his doctors attributed the shaking to a "normal aging phenomenon." He noted that while he was initially concerned enough to seek a professional diagnosis, he felt relieved to learn the tremors were not related to a progressive disease.